Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pu27 Palmi
- Development stage
- Preclinical
- Lead developer
- University of Louisville
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
Pu27 Palmi is a palmitoylated (lipid-modified) G-quadruplex-forming oligonucleotide designed to target the c-MYC oncogene promoter. It is derived from the 27-nucleotide guanine-rich sequence (Pu27) located within the nuclease hypersensitive element (NHE) III1 of the c-MYC promoter region. By conjugating Pu27 with palmitic acid (palmitate), the oligonucleotide achieves enhanced G-quadruplex stability, improved cellular uptake, and reduced blood clearance compared to unmodified Pu27. Pu27 Palmi binds to the complementary C-rich strand of the NHEIII1 region, stabilizing the G-quadruplex structure and subsequently downregulating c-MYC transcription. This downregulation leads to decreased expression of c-MYC target genes (such as hTERT and VEGF), inhibiting cell proliferation and inducing apoptosis in cancer cells, particularly in triple-negative breast cancer (TNBC) and leukemia.
- Other names
- Pu27 palmitatePu-27 palmitatePu 27 palmitatelipid-modified Pu27palmitoyl-Pu27palmitoyl-Pu-27palmitoyl-Pu 27palmitoylated Pu27
02
Targets
MYC (MYC proto-oncogene protein)c-MYC promoter Pu27/NHEIII1 G-quadruplex-forming DNA
Beyond the preview
Go deeper on Pu27 Palmi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pu27 Palmi.